ORs for the achievement of CR/CRi, ED, and HRs for OS according to the linear multivariable logistic regression models
| . | Complete remission . | Early death . | OS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR . | 95% CI . | P . | OR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| TDT | 0.991 | 0.974-1.007 | .254 | 1.005 | 0.971-1.041 | .757 | 1.002 | 0.993-1.011 | .617 |
| ELN risk group | |||||||||
| Intermediate | Reference category | Reference category | Reference category | ||||||
| Favorable | 2.311 | 1.647-3.243 | <.001 | 0.927 | 0.525-1.638 | .795 | 0.578 | 0.491-0.679 | <.001 |
| Adverse | 0.470 | 0.359-0.616 | <.001 | 1.262 | 0.699-2.277 | .440 | 1.600 | 1.861-1.8547 | <.001 |
| Missing | 0.452 | 0.322-0.633 | <.001 | 2.236 | 1.207-4.141 | .011 | 1.410 | 1.175-1.693 | <.001 |
| Age, per 10 y | 0.613 | 0.556-0.676 | <.001 | 1.401 | 1.163-1.689 | <.001 | 1.422 | 1.355-1.492 | <.001 |
| Log2 of WBC in ×109/L | 0.997 | 0.950-1.048 | .916 | 1.081 | 0.975-1.199 | .140 | 1.003 | 0.978-1.029 | .817 |
| Log2 of LDH in U/L | 0.846 | 0.750-0.954 | .006 | 1.027 | 0.810-1.301 | .829 | 1.195 | 1.126-1.269 | <.001 |
| AML status | |||||||||
| De novo | Reference category | Reference category | Reference category | ||||||
| sAML | 0.714 | 0.538-0.949 | .020 | 0.577 | 0.278-1.195 | .138 | 1.221 | 1.049-1.421 | .009 |
| tAML | 0.804 | 0.567-1.140 | .221 | 1.184 | 0.630-2.226 | .600 | 1.358 | 1.130-1.631 | .001 |
| Missing | 0.729 | 0.157-3.394 | .687 | 2.619 | 0.301-22.82 | .383 | 1.291 | 0.533-3.123 | .572 |
| ECOG 0-1 | 1.610 | 1.209-2.143 | .001 | 0.497 | 0.304-0.811 | .005 | 0.779 | 0.669-0.907 | .001 |
| HCT-CI >2 | 0.802 | 0.622-1.034 | .088 | 1.315 | 0.810-2.135 | .269 | 1.123 | 0.981-1.285 | .093 |
| . | Complete remission . | Early death . | OS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR . | 95% CI . | P . | OR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| TDT | 0.991 | 0.974-1.007 | .254 | 1.005 | 0.971-1.041 | .757 | 1.002 | 0.993-1.011 | .617 |
| ELN risk group | |||||||||
| Intermediate | Reference category | Reference category | Reference category | ||||||
| Favorable | 2.311 | 1.647-3.243 | <.001 | 0.927 | 0.525-1.638 | .795 | 0.578 | 0.491-0.679 | <.001 |
| Adverse | 0.470 | 0.359-0.616 | <.001 | 1.262 | 0.699-2.277 | .440 | 1.600 | 1.861-1.8547 | <.001 |
| Missing | 0.452 | 0.322-0.633 | <.001 | 2.236 | 1.207-4.141 | .011 | 1.410 | 1.175-1.693 | <.001 |
| Age, per 10 y | 0.613 | 0.556-0.676 | <.001 | 1.401 | 1.163-1.689 | <.001 | 1.422 | 1.355-1.492 | <.001 |
| Log2 of WBC in ×109/L | 0.997 | 0.950-1.048 | .916 | 1.081 | 0.975-1.199 | .140 | 1.003 | 0.978-1.029 | .817 |
| Log2 of LDH in U/L | 0.846 | 0.750-0.954 | .006 | 1.027 | 0.810-1.301 | .829 | 1.195 | 1.126-1.269 | <.001 |
| AML status | |||||||||
| De novo | Reference category | Reference category | Reference category | ||||||
| sAML | 0.714 | 0.538-0.949 | .020 | 0.577 | 0.278-1.195 | .138 | 1.221 | 1.049-1.421 | .009 |
| tAML | 0.804 | 0.567-1.140 | .221 | 1.184 | 0.630-2.226 | .600 | 1.358 | 1.130-1.631 | .001 |
| Missing | 0.729 | 0.157-3.394 | .687 | 2.619 | 0.301-22.82 | .383 | 1.291 | 0.533-3.123 | .572 |
| ECOG 0-1 | 1.610 | 1.209-2.143 | .001 | 0.497 | 0.304-0.811 | .005 | 0.779 | 0.669-0.907 | .001 |
| HCT-CI >2 | 0.802 | 0.622-1.034 | .088 | 1.315 | 0.810-2.135 | .269 | 1.123 | 0.981-1.285 | .093 |
ORs: 95% confidence intervals and P values for Wald test.
See Table 1 for expansion of abbreviations.